Human AGTR1 adenoviral particles

Angiotensin II receptor type 1 (AGTR1), also commonly referred to as AT1R, encodes a key G protein-coupled receptor (GPCR) that is the primary effector of the potent vasoactive peptide hormone angiotensin II (Ang II). The receptor is a central component of the renin-angiotensin-aldosterone system (RAAS), a major regulator of cardiovascular and renal homeostasis. Upon binding to Ang II, AGTR1 primarily couples to Gq proteins, initiating an intracellular signaling cascade that includes phospholipase C (PLC) activation, inositol triphosphate (IP3)-mediated calcium release, diacylglycerol (DAG)-activated protein kinase C (PKC), and downstream mitogen-activated protein kinase (MAPK) pathways. These events trigger a robust physiological response that includes vasoconstriction, adrenal aldosterone secretion (promoting sodium and water retention), increased sympathetic nervous system activity, cell proliferation, inflammation, and fibrosis. Therefore, dysregulated or chronic overactivation of AGTR1 signaling is fundamentally implicated in the pathogenesis of essential hypertension, cardiac hypertrophy, heart failure, vascular remodeling, and chronic kidney disease.

Human AGTR1 adenoviral particles are an advanced molecular biology tool designed to efficiently deliver and express the full-length human AGTR1 gene (or specific variants thereof) into a variety of mammalian cell types, both in vitro and in vivo. These particles are based on a replication-defective adenovirus serotype 5 (Ad5) that blocks viral replication by deleting the essential E1 region and the usual E3 region, while maintaining high transduction efficiency, making them safe for research use. Using these particles, researchers have established cell models that overexpress AGTR1, enabling detailed studies of receptor signaling mechanisms (e.g., G protein coupling bias, β-Arrestin recruitment), ligand binding properties, internalization and recycling kinetics, interactions with accessory proteins, and the functional consequences of receptor activation or blockade.